ELVN vs. ABCL, VRNA, MNKD, COLL, MIRM, PCRX, SYRE, BLTE, PRTA, and GYRE
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include AbCellera Biologics (ABCL), Verona Pharma (VRNA), MannKind (MNKD), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Belite Bio (BLTE), Prothena (PRTA), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical preparations" industry.
Enliven Therapeutics (NASDAQ:ELVN) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.
Enliven Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Enliven Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics received 47 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 77.27% of users gave AbCellera Biologics an outperform vote.
In the previous week, AbCellera Biologics had 17 more articles in the media than Enliven Therapeutics. MarketBeat recorded 24 mentions for AbCellera Biologics and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.67 beat AbCellera Biologics' score of 0.18 indicating that Enliven Therapeutics is being referred to more favorably in the media.
Enliven Therapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 45.11%. AbCellera Biologics has a consensus target price of $16.17, suggesting a potential upside of 322.11%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Enliven Therapeutics.
Enliven Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -410.47%. AbCellera Biologics' return on equity of -12.61% beat Enliven Therapeutics' return on equity.
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 45.8% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 32.5% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
AbCellera Biologics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
